Ratings SK bioscience Co.,Ltd.

Equities

A302440

KR7302440003

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
57,400 ^KRW	-0.17%		0.00%	-20.28%

03-28	SK Bioscience Signs Deal with Sanofi for Five Vaccine Types	MT
03-07	SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past twelve months, EPS forecast has been revised upwards.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
Most analysts recommend that the stock should be sold or reduced.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SK BIOSCIENCE CO.,LTD.	-20.28%	3.2B	B-
CSL LIMITED	-4.66%	86.13B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B	A-
BIOGEN INC.	-19.27%	30.42B	B-
UCB	+57.86%	25.23B	A
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B	C
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B	D+
INCYTE CORPORATION	-17.69%	11.6B	B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B	B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes